WO2007094340A1 - 血管拡張剤 - Google Patents
血管拡張剤 Download PDFInfo
- Publication number
- WO2007094340A1 WO2007094340A1 PCT/JP2007/052569 JP2007052569W WO2007094340A1 WO 2007094340 A1 WO2007094340 A1 WO 2007094340A1 JP 2007052569 W JP2007052569 W JP 2007052569W WO 2007094340 A1 WO2007094340 A1 WO 2007094340A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pro
- vasodilator
- vpp
- peptide
- ipp
- Prior art date
Links
- 229940124549 vasodilator Drugs 0.000 title claims abstract description 27
- 239000003071 vasodilator agent Substances 0.000 title claims abstract description 27
- DOFAQXCYFQKSHT-SRVKXCTJSA-N Val-Pro-Pro Chemical compound CC(C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 DOFAQXCYFQKSHT-SRVKXCTJSA-N 0.000 claims abstract description 34
- 108010015385 valyl-prolyl-proline Proteins 0.000 claims abstract description 14
- 239000004480 active ingredient Substances 0.000 claims abstract description 13
- 239000007857 degradation product Substances 0.000 claims abstract description 5
- 230000017854 proteolysis Effects 0.000 claims abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 23
- RWCOTTLHDJWHRS-YUMQZZPRSA-N Pro-Pro Chemical compound OC(=O)[C@@H]1CCCN1C(=O)[C@H]1NCCC1 RWCOTTLHDJWHRS-YUMQZZPRSA-N 0.000 claims description 12
- 108010077112 prolyl-proline Proteins 0.000 claims description 12
- 235000013376 functional food Nutrition 0.000 abstract description 16
- 230000000304 vasodilatating effect Effects 0.000 abstract description 14
- 210000003989 endothelium vascular Anatomy 0.000 abstract description 11
- 206010003210 Arteriosclerosis Diseases 0.000 abstract description 9
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract description 9
- 230000001419 dependent effect Effects 0.000 abstract description 9
- 239000003795 chemical substances by application Substances 0.000 abstract description 2
- 230000003449 preventive effect Effects 0.000 abstract description 2
- FQYQMFCIJNWDQZ-CYDGBPFRSA-N Ile-Pro-Pro Chemical compound CC[C@H](C)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(O)=O)CCC1 FQYQMFCIJNWDQZ-CYDGBPFRSA-N 0.000 abstract 2
- 108010031424 isoleucyl-prolyl-proline Proteins 0.000 abstract 2
- JREYOWJEWZVAOR-UHFFFAOYSA-N triazanium;[3-methylbut-3-enoxy(oxido)phosphoryl] phosphate Chemical compound [NH4+].[NH4+].[NH4+].CC(=C)CCOP([O-])(=O)OP([O-])([O-])=O JREYOWJEWZVAOR-UHFFFAOYSA-N 0.000 description 17
- 235000013305 food Nutrition 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 150000001413 amino acids Chemical group 0.000 description 7
- 235000018102 proteins Nutrition 0.000 description 7
- 102000004169 proteins and genes Human genes 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- 230000024883 vasodilation Effects 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- -1 for example Chemical class 0.000 description 4
- 208000023589 ischemic disease Diseases 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000243 solution Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000011632 Caseins Human genes 0.000 description 3
- 108010076119 Caseins Proteins 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 239000005018 casein Substances 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 210000003038 endothelium Anatomy 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 3
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 2
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000010339 dilation Effects 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000003531 protein hydrolysate Substances 0.000 description 2
- 239000012264 purified product Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000020183 skimmed milk Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- ZPGDWQNBZYOZTI-UHFFFAOYSA-N 1-(9h-fluoren-9-ylmethoxycarbonyl)pyrrolidine-2-carboxylic acid Chemical compound OC(=O)C1CCCN1C(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 ZPGDWQNBZYOZTI-UHFFFAOYSA-N 0.000 description 1
- 239000005541 ACE inhibitor Substances 0.000 description 1
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 description 1
- 206010007556 Cardiac failure acute Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010061435 Enalapril Proteins 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 201000001431 Hyperuricemia Diseases 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- RHQDFWAXVIIEBN-UHFFFAOYSA-N Trifluoroethanol Chemical compound OCC(F)(F)F RHQDFWAXVIIEBN-UHFFFAOYSA-N 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
- 235000020244 animal milk Nutrition 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- YEESUBCSWGVPCE-UHFFFAOYSA-N azanylidyneoxidanium iron(2+) pentacyanide Chemical compound [Fe++].[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.N#[O+] YEESUBCSWGVPCE-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000000496 cardiotonic agent Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000003205 diastolic effect Effects 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 229940030606 diuretics Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000013583 drug formulation Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
- 229960000873 enalapril Drugs 0.000 description 1
- 230000008753 endothelial function Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- IOPLHGOSNCJOOO-UHFFFAOYSA-N methyl 3,4-diaminobenzoate Chemical compound COC(=O)C1=CC=C(N)C(N)=C1 IOPLHGOSNCJOOO-UHFFFAOYSA-N 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 235000020124 milk-based beverage Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 229960002460 nitroprusside Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 1
- 229960001802 phenylephrine Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- ZERULLAPCVRMCO-UHFFFAOYSA-N sulfure de di n-propyle Natural products CCCSCCC ZERULLAPCVRMCO-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
- 235000021246 κ-casein Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Definitions
- the present invention relates to a vasodilator exhibiting vascular endothelium-dependent vasodilatory activity and a functional food exhibiting such action.
- Ischemic diseases such as myocardial infarction and cerebral infarction, which are terminal images of arteriosclerotic diseases, are the most common cause of death in Japan along with cancer.
- Risk factors for arteriosclerosis include hyperlipidemia, hypertension, diabetes, smoking, obesity, hyperuricemia, aging, stress, etc., which are intertwined with each other and cause vascular disorders. For this reason, even if the degree of each risk factor is mild, the risk increases additively and synergistically due to their overlap, and the risk of ischemic disease also increases.
- Non-patent literature 1 or 2 does not correlate the blood cholesterol level with the onset of arteriosclerosis
- non-patent literature 3 shows a change in the degree of arteriosclerosis even if the hypertension state is suppressed.
- Non-Patent Document 4 describes that even when an angiotensin converting enzyme inhibitor containing enalapril as an active ingredient is administered, no arteriosclerosis inhibitory action is observed.
- Non-Patent Document 5 when infarcted ischemic diseases such as acute heart failure occur, according to Non-Patent Document 5, nitroprusside, nitroglycerin, etc. Vasodilators, diuretics, and cardiotonic drugs are necessary.
- the tripeptide has the inhibitory activity of angiotensin I-converting enzyme that exhibits the blood pressure-lowering action and the anti-stress action. Due to this, it cannot be said that the tripeptide force has an anti-arteriosclerotic action and cannot have a vasodilating action.
- arteriosclerosis is a pathological condition in which the arterial wall is thickened and loses its elasticity, and in recent years, damage to vascular endothelium and reduced function are cited as one of the causes of such symptoms. Therefore, a vasodilator that depends on the vascular endothelium can be expected to have an arteriosclerosis inhibitory action.
- Patent Document 1 JP-A-6-197786
- Patent Document 2 Japanese Patent Laid-Open No. 11-100328
- Non-Patent Document 1 Food Science 257 (1999) p20— 25
- Non-Patent Document 2 Atherosclerosis 151 (2000) p501— 508
- Non-Patent Document 3 Circulation 104 (2001) p2391— 2394
- Non-Patent Literature 4 international Journal of Cardiology 81 (2001) pl07— 115
- Non-Patent Literature 5 Separate volume 'Ayumi of Medicine Cardiovascular Diseases-state of arts ver.2 (2001) p332- 33
- An object of the present invention is to provide a vasodilator having a vascular endothelium-dependent vasodilatory action.
- Another object of the present invention is to provide a functional food that can be used on a daily basis, has excellent safety, and has a vasodilator-dependent vasodilatory action.
- a vasodilator comprising at least one peptide of Val Pro Pro and lie Pro Pro as an active ingredient.
- the present invention also provides a vasodilator comprising a proteolysate containing Val Pro Pro and Z or He Pro Pro as an active ingredient.
- a functional food having at least one peptide of Val Pro Pro and lie Pro Pro as an active ingredient and having a vasodilating action is provided.
- a functional food having a vasodilatory action comprising a protein fragment containing Val Pro Pro and Z or He Pro Pro as an active ingredient.
- At least one peptide of Val Pro Pro and lie Pro Pro, or Val Pro Pro and Z or He Pro Pro for producing a vasodilator or a functional food having a vasodilator action is provided.
- Use of the proteolysate containing is provided.
- At least one peptide of Val Pro Pro and lie Pro Pro Alternatively, a method for dilating a blood vessel is provided, in which an effective amount of a protein degradation product containing Val Pro Pro and Z or He Pro Pro is administered to an animal.
- the vasodilator and the functional food of the present invention contain Val Pro Pro and Z or He Pro Pro derived from animal milk casein and the like, and further a protein degradation product containing at least one of them as an active ingredient. It is excellent in safety and exhibits a vascular endothelium-dependent vasodilatory effect. In particular, a functional food can be ingested regularly.
- the vasodilator of the present invention is useful for ensuring blood circulation in ischemic diseases such as myocardial infarction and cerebral infarction, and biased toward contraction due to aging, lifestyle-related diseases, etc. It can relax the blood vessels and prevent arteriosclerosis and prevention of stiff shoulders, coldness and thrombosis related to blood flow disorders.
- the functional food of the present invention is useful as a health food or a food for specified health use that displays efficacy for various symptoms and diseases such as stiff shoulders, coldness, and blood clots related to vasodilation and blood flow disorders. It is.
- FIG. 1 is a graph showing the results of a vasodilation test performed in Example 1 and Comparative Example 1.
- FIG. 2 is a graph showing the results of a test for confirming endothelium dependence of a vasodilator response performed in Example 1.
- vasodilator and functional food of the present invention contain Val Pro Pro and Z or He Pro Pro (hereinafter, these tripeptides are abbreviated as VPP and IPP, respectively) or a protein degradation product containing at least one of these as an active ingredient. .
- the tripeptides are pharmacologically acceptable salts, for example, inorganic acid salts such as hydrochloride, sodium salt and phosphate, and organic salts such as citrate, maleate, fumarate, tartrate and lactate. It may be a salt added with a salt such as an acid salt.
- inorganic acid salts such as hydrochloride, sodium salt and phosphate
- organic salts such as citrate, maleate, fumarate, tartrate and lactate. It may be a salt added with a salt such as an acid salt.
- Examples of the method for preparing the tripeptide include a method of decomposing and purifying a peptide or protein having the amino acid sequence of VPP and Z or IPP by fermentation with a microorganism, a method of enzymatic hydrolysis, and a synthetic method. Obtainable. Details above Patent Documents 1 and 2 can be referred to.
- a peptide or protein having an amino acid sequence of VPP and Z or IPP a fermented product containing at least one peptide of VPP and IPP, or a purified product thereof, fermented by a microorganism, or VPP
- a hydrolyzate containing at least one peptide of VPP and IPP, or a purified product thereof, which is obtained by decomposing a peptide or protein having an amino acid sequence of Z or IPP with an enzyme can also be used.
- the amount of tripeptide per day is usually 10 g to 10 g, particularly 1 mg to: About Lg is preferable.
- Administration of the vasodilator can be adjusted depending on the symptoms of the disease. Single and continuous parenteral administration are appropriate for acute symptoms. For chronic symptoms and prophylactic use, it is preferable to ingest orally for 30 days or more.
- Examples of the administration method of the vasodilator of the present invention include oral administration and parenteral administration.
- Parenteral administration includes topical, transdermal, intravenous, intramuscular, subcutaneous, intradermal, intraperitoneal, intrathoracic, intrathecal, etc., and direct administration to the affected area is also possible.
- the form of the vasodilator of the present invention can be determined according to the administration method, and can be in the form of a preparation. Examples include tablets, pills, hard capsules, soft capsules, microcapsules, powders, granules, liquids, suspensions, and emulsions.
- the formulation may be carried out, for example, as necessary, as a pharmaceutically acceptable carrier, adjuvant, excipient, excipient, preservative, stabilizer, binder, PH regulator, buffer, thickener. It is manufactured in a unit dosage form that is generally required for the practice of the drug formulation, using agents, gelling agents, preservatives, antioxidants, etc.
- the functional food of the present invention can be a health food or a food for specified health use that can display or promote the effects for various diseases related to vasodilation and blood flow disorders.
- the intake to obtain such effects, particularly vasodilatory action and the ameliorating action associated with it is 1
- the amount of the tripeptide per day is usually about 10 g to 10 g, particularly about lmg to about Lg. In addition, depending on the number of intakes per day, It is also possible to lower the amount taken in terms of the tripeptide amount.
- the period of ingestion of the functional food of the present invention is not particularly limited, and it is preferably ingested for a long period of time for improvement of chronic symptoms and preventive use. In order to obtain the above-mentioned effects, it is preferable to take it regularly for usually 30 days or more, especially about 3 to 12 months.
- the functional food of the present invention can be produced by a method of blending the tripeptide as an active ingredient or a food material containing the tripeptide into various foods, etc., it is assumed that all foods and beverages are in a form. be able to.
- it can be in the form of tablet confectionery, yogurt, milk beverage, dairy product, alcoholic beverage, soft drink, powdered or granular food, capsule food, various fortified or supplementary foods, and the like.
- the functional food of the present invention can usually contain various additives that can be added to food.
- IPP and VPP were synthesized by the organic chemical synthesis method shown below.
- the synthesis was performed by a solid phase method using an automatic peptide synthesizer (PSSM-8 type) manufactured by Shimadzu Corporation.
- PSSM-8 type automatic peptide synthesizer
- Fmoc 2-Chlorotrityl type polystyrene rosin as a solid support, with proline bound with amino group protected by fluorenylmethyloxycarboxyl group (hereinafter abbreviated as Fmoc) 50 mg of rosin was used (registered trademark SynProP mark Res in, manufactured by Shimadzu Corporation).
- Fmoc-Ile, Fmoc-Pro, and Fmoc-Val in which the amino group was protected with the Fmoc group were reacted in 100 / z mol in accordance with the peptide sequence in the usual manner to obtain a peptide-bonded resin.
- reaction solution A (10% by volume acetic acid, 10% by volume trifluoroethanol, 80% by volume dichloromethane)
- reaction solution B 82.5% by volume trifluoroacetic acid, 3% by volume ethyl methyl sulfide, 5% by volume pure water, 5% by volume thioanol, 2.5% by volume ethanol
- reaction solution B 82.5% by volume trifluoroacetic acid, 3% by volume ethyl methyl sulfide, 5% by volume pure water, 5% by volume thioanol, 2.5% by volume ethanol
- the thoracic aorta was removed from Wistar rats and cut at a width of 2 mm to produce an aortic ring.
- the ring was attached to a Magnus apparatus (manufactured by Labo Support, product name: Micro Tissue Gunbath MTB-1Z) and equilibrated with a certain tension.
- the contraction response of the aortic ring was confirmed with 50 mM KC1.
- a specimen of the aortic ring contracted with M Phenylephrine and a stable contraction was obtained: With LM acetylcholine, vascular endothelium-dependent dilation was observed, and endothelial function was 0 confirmed to be held
- the aortic ring was pre-contracted with 1 ⁇ fue-rephrin and then prepared in a synthetic example.
- VPP and ⁇ added by increasing the concentration by 10 times 10- 9 Micromax were observed extended reaction from the change in tension of the aorta rings.
- VPP and IPP vasodilation was highly dependent on vascular endothelium. The result is shown in figure 2.
- VPP or IPP has activity in the peptide state.
- vasodilatory pharmaceutical composition and a vasodilatory health food composition containing peptides obtained by hydrolyzing various milk protein-derived proteins as active ingredients have been reported. Since amino acid sequences including VPP and IPP are known to exist in / 3-casein and ⁇ -casein, do peptides contained in the production examples described in the publication contain VPP and IPP? I confirmed.
- skim milk powder which is a protein raw material containing / 3-casein and K-casein
- 1 kg of skim milk powder was suspended in 2 liters of warm water, adjusted to pH 7.5, 40 g of Samoaze (manufactured by Daiwa Kasei Co., Ltd.) was added, and the mixture was reacted at 50 ° C. for 16 hours. After the reaction, the enzyme was inactivated by heating at 100 ° C. for 10 minutes to produce a hydrolyzed peptide.
- LCZMS high-speed chromatograph mass spectrometer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Gastroenterology & Hepatology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
Claims
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP07714138.0A EP1992353B1 (en) | 2006-02-14 | 2007-02-14 | Vasodilator |
BRPI0707827-7A BRPI0707827A2 (pt) | 2006-02-14 | 2007-02-14 | vasodilatador |
US12/279,218 US20090234097A1 (en) | 2006-02-14 | 2007-02-14 | Vasodilator |
CA2642537A CA2642537C (en) | 2006-02-14 | 2007-02-14 | Vasodilator |
JP2008500513A JPWO2007094340A1 (ja) | 2006-02-14 | 2007-02-14 | 血管拡張剤 |
EA200870259A EA200870259A1 (ru) | 2006-02-14 | 2007-02-14 | Сосудорасширяющее средство |
CN2007800131650A CN101420968B (zh) | 2006-02-14 | 2007-02-14 | 血管扩张药 |
US13/175,340 US20110263516A1 (en) | 2006-02-14 | 2011-07-01 | Vasodilator |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2006035944 | 2006-02-14 | ||
JP2006-035944 | 2006-02-14 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/175,340 Continuation US20110263516A1 (en) | 2006-02-14 | 2011-07-01 | Vasodilator |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2007094340A1 true WO2007094340A1 (ja) | 2007-08-23 |
Family
ID=38371518
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2007/052569 WO2007094340A1 (ja) | 2006-02-14 | 2007-02-14 | 血管拡張剤 |
Country Status (10)
Country | Link |
---|---|
US (2) | US20090234097A1 (ja) |
EP (1) | EP1992353B1 (ja) |
JP (1) | JPWO2007094340A1 (ja) |
KR (1) | KR20080095898A (ja) |
CN (1) | CN101420968B (ja) |
BR (1) | BRPI0707827A2 (ja) |
CA (1) | CA2642537C (ja) |
EA (1) | EA200870259A1 (ja) |
TW (1) | TW200808338A (ja) |
WO (1) | WO2007094340A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012036191A1 (ja) * | 2010-09-16 | 2012-03-22 | カルピス株式会社 | 脳機能改善用組成物および脳機能を改善する方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090130303A (ko) * | 2007-03-27 | 2009-12-22 | 칼피스가부시키가이샤 | 신부전 예방제 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0162032A2 (en) | 1984-05-04 | 1985-11-21 | Washington University | Novel atrial peptide |
JPH0640944A (ja) | 1992-07-23 | 1994-02-15 | Calpis Food Ind Co Ltd:The | アンジオテンシン変換酵素阻害剤及びその製造法 |
WO1999016862A1 (fr) | 1997-09-26 | 1999-04-08 | Calpis Co., Ltd. | Bacterie du genre lactobacillus helveticus ayant une grande capacite de production de tripeptides, produit laitier fermente et son procede de preparation |
WO2000041572A1 (fr) | 1999-01-11 | 2000-07-20 | Calpis Co., Ltd. | Procede de production de lait fermente renfermant un peptide inhibiteur de l'enzyme de conversion de l'angiotensine et procede de production de lactoserum |
JP2003513636A (ja) | 1999-11-01 | 2003-04-15 | ヴァリオ・オサケ・ユキテュア | 抗高血圧性トリペプチドを含有する産物をつくる方法 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3805804B2 (ja) * | 1994-09-14 | 2006-08-09 | 森永乳業株式会社 | 動脈硬化防止剤 |
-
2007
- 2007-02-14 BR BRPI0707827-7A patent/BRPI0707827A2/pt not_active IP Right Cessation
- 2007-02-14 CA CA2642537A patent/CA2642537C/en active Active
- 2007-02-14 CN CN2007800131650A patent/CN101420968B/zh active Active
- 2007-02-14 JP JP2008500513A patent/JPWO2007094340A1/ja active Pending
- 2007-02-14 US US12/279,218 patent/US20090234097A1/en not_active Abandoned
- 2007-02-14 WO PCT/JP2007/052569 patent/WO2007094340A1/ja active Search and Examination
- 2007-02-14 EP EP07714138.0A patent/EP1992353B1/en not_active Not-in-force
- 2007-02-14 TW TW096105561A patent/TW200808338A/zh unknown
- 2007-02-14 EA EA200870259A patent/EA200870259A1/ru unknown
- 2007-02-14 KR KR1020087022199A patent/KR20080095898A/ko not_active Application Discontinuation
-
2011
- 2011-07-01 US US13/175,340 patent/US20110263516A1/en not_active Abandoned
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0162032A2 (en) | 1984-05-04 | 1985-11-21 | Washington University | Novel atrial peptide |
JPH0640944A (ja) | 1992-07-23 | 1994-02-15 | Calpis Food Ind Co Ltd:The | アンジオテンシン変換酵素阻害剤及びその製造法 |
WO1999016862A1 (fr) | 1997-09-26 | 1999-04-08 | Calpis Co., Ltd. | Bacterie du genre lactobacillus helveticus ayant une grande capacite de production de tripeptides, produit laitier fermente et son procede de preparation |
EP1016709A1 (en) | 1997-09-26 | 2000-07-05 | Calpis Co., Ltd. | Lactobacillus helveticus bacterium having high capability of producing tripeptide, fermented milk product, and process for preparing the same |
WO2000041572A1 (fr) | 1999-01-11 | 2000-07-20 | Calpis Co., Ltd. | Procede de production de lait fermente renfermant un peptide inhibiteur de l'enzyme de conversion de l'angiotensine et procede de production de lactoserum |
JP2003513636A (ja) | 1999-11-01 | 2003-04-15 | ヴァリオ・オサケ・ユキテュア | 抗高血圧性トリペプチドを含有する産物をつくる方法 |
Non-Patent Citations (5)
Title |
---|
BESSATSU IGAKU NO AYUMI, JUNKANKI SHIKKANN, 2001, pages 332 - 334 |
INTERNATIONAL JOURNAL OF CARDIOLOGY, vol. 81, 2001, pages 107 - 115 |
PRASAD A. ET AL.: "Abnormal flow-mediated epicardial vasomotion in human coronary arteries is improved by angiotensin-converting enzyme inhibition", JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 33, no. 3, 1999, pages 796 - 804, XP003016680 * |
PRASAD, A. ET AL., JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, vol. 33, no. 3, 1999, pages 796 - 804 |
See also references of EP1992353A4 |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012036191A1 (ja) * | 2010-09-16 | 2012-03-22 | カルピス株式会社 | 脳機能改善用組成物および脳機能を改善する方法 |
CN103108646A (zh) * | 2010-09-16 | 2013-05-15 | 可尔必思株式会社 | 脑功能改善用组合物及改善脑功能的方法 |
JPWO2012036191A1 (ja) * | 2010-09-16 | 2014-02-03 | カルピス株式会社 | 脳機能改善用組成物および脳機能を改善する方法 |
CN103108646B (zh) * | 2010-09-16 | 2014-06-11 | 可尔必思株式会社 | 脑功能改善用组合物及改善脑功能的方法 |
US8916524B2 (en) | 2010-09-16 | 2014-12-23 | Calpis Co., Ltd. | Composition for improving brain function and method for improving brain function |
Also Published As
Publication number | Publication date |
---|---|
CA2642537A1 (en) | 2007-08-23 |
BRPI0707827A2 (pt) | 2011-05-10 |
CN101420968B (zh) | 2011-12-21 |
CA2642537C (en) | 2013-04-09 |
US20090234097A1 (en) | 2009-09-17 |
US20110263516A1 (en) | 2011-10-27 |
EA200870259A1 (ru) | 2009-02-27 |
EP1992353B1 (en) | 2014-05-07 |
JPWO2007094340A1 (ja) | 2009-07-09 |
EP1992353A1 (en) | 2008-11-19 |
EP1992353A4 (en) | 2009-12-23 |
CN101420968A (zh) | 2009-04-29 |
KR20080095898A (ko) | 2008-10-29 |
TW200808338A (en) | 2008-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR20110060940A (ko) | 항염증성 펩티드 | |
CA2185450A1 (en) | Eating suppressant peptides | |
JP2007523940A (ja) | 抗高血圧ペプチド | |
WO2001068113A1 (en) | Anti-hypertensive peptides | |
KR20140026295A (ko) | 안지오텐신-i 전환 효소 저해능을 나타내는 펩타이드를 유효성분으로 포함하는 심혈관계 질환 예방 또는 치료용 약학적 조성물 | |
WO2001068114A1 (en) | Novel peptides with anti-hypertensive activity | |
CA2549185C (en) | Peptide inhibiting angiotensin converting enzyme | |
JP2013071897A (ja) | アンジオテンシン変換酵素阻害性降圧ペプチド組成物の製造方法 | |
KR20090129489A (ko) | 간질환의 예방 또는 치료용 조성물 | |
WO2005118619A1 (ja) | 血圧降下作用を有するジペプチド | |
WO2007094340A1 (ja) | 血管拡張剤 | |
JP5642346B2 (ja) | 動脈硬化予防剤、血管内膜の肥厚抑制剤及び血管内皮の収縮・拡張機能改善剤 | |
US7763281B2 (en) | Antihypertensive peptide and use thereof | |
JP4429031B2 (ja) | アンギオテンシン変換酵素阻害ペプチド | |
JP2000505074A (ja) | アンジオテンシン転換酵素阻害剤 | |
KR20130113707A (ko) | 안지오텐신 전환효소 저해활성을 갖는 신규 펩타이드 및 그의 용도 | |
JP7339650B2 (ja) | ペプチド | |
JP4618670B2 (ja) | At1受容体結合阻害活性及びace阻害活性ペプチド | |
MX2008010328A (en) | Vasodilator | |
JP3992143B2 (ja) | 新規生理活性ペプチド | |
JP2015209400A (ja) | 新規トリペプチド及びペプチド含有組成物、並びにそれらの使用、それらを有効成分として含有する摂食抑制剤、抗肥満剤、動脈弛緩剤、血圧降下剤、メタボリックシンドローム予防改善剤、又は食欲調節用の食品組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2008500513 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2642537 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/a/2008/010328 Country of ref document: MX |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 7680/DELNP/2008 Country of ref document: IN Ref document number: 1020087022199 Country of ref document: KR Ref document number: 2007714138 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200870259 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200780013165.0 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 12279218 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0707827 Country of ref document: BR Kind code of ref document: A2 Effective date: 20080814 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) |